Recent Investment Analysts’ Ratings Changes for Kodiak Sciences (KOD)

A number of research firms have changed their ratings and price targets for Kodiak Sciences (NASDAQ: KOD):

• 10/12/2026 – Kodiak Sciences had its price target raised by HC Wainwright from $96.00 to $126.00. They now have a “buy” rating on the stock.
• 10/6/2026 – Kodiak Sciences was downgraded by Weiss Ratings from “sell (d-)” to “sell (e+)”.
• 10/4/2026 – Kodiak Sciences was upgraded by Wall Street Zen from “strong sell” to “sell”.
• 9/30/2026 – Kodiak Sciences had its “neutral” rating reaffirmed by The Goldman Sachs Group, Inc.. They now have a $103.00 price target on the stock.
• 9/28/2026 – Kodiak Sciences had its “buy” rating reaffirmed by Jefferies Financial Group Inc.. They now have a $112.00 price target on the stock.
• 9/28/2026 – Kodiak Sciences had its price target raised by Lifesci Capital from $85.00 to $145.00. They now have an “outperform” rating on the stock.
• 9/28/2026 – Kodiak Sciences had its price target raised by UBS Group AG from $80.00 to $120.00. They now have a “buy” rating on the stock.
• 9/28/2026 – Kodiak Sciences had its price target raised by HC Wainwright from $58.00 to $96.00. They now have a “buy” rating on the stock.
• 9/26/2026 – Kodiak Sciences was downgraded by Wall Street Zen from “sell” to “strong sell”.
• 9/24/2026 – Kodiak Sciences is now covered by The Goldman Sachs Group, Inc.. They set a “neutral” rating and a $36.00 price target on the stock.
• 9/24/2026 – Kodiak Sciences is now covered by The Goldman Sachs Group, Inc.. They set a “neutral” rating and a $36.00 price target on the stock.
• 9/17/2026 – Kodiak Sciences had its “buy” rating reaffirmed by HC Wainwright. They now have a $58.00 price target on the stock.
• 8/17/2026 – Kodiak Sciences had its “buy” rating reaffirmed by HC Wainwright. They now have a $58.00 price target on the stock.

Insider Buying and Selling

In other Kodiak Sciences news, Director Bros. Advisors Lp Baker acquired 807,840 shares of the firm’s stock in a transaction that occurred on Monday, September 28th. The shares were purchased at an average cost of $72.57 per share, for a total transaction of $58,624,948.80. Following the completion of the acquisition, the director owned 19,121,134 shares of the company’s stock, valued at approximately $1,387,620,694.38. The trade was a 4.41% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at this hyperlink. Insiders purchased 1,941,755 shares of company stock valued at $156,986,026 in the last 90 days. Corporate insiders own 44.40% of the company’s stock.

Kodiak Sciences Inc (NASDAQ: KOD) is a clinical-stage biopharmaceutical company focused on developing medicines for serious retinal diseases. The company’s research is centered on its Antibody Biopolymer Conjugate (ABC) platform, which is designed to combine antibody-based therapies with biopolymer technology to potentially extend the duration of treatment in the eye.

Kodiak’s lead programs have focused on ophthalmic diseases involving abnormal blood-vessel growth or leakage, including wet age-related macular degeneration, diabetic macular edema and retinal vein occlusion.